Citigroup’s Next Move: NewAmsterdam’s Inducement Grants!

Dividend Policy & History

Citigroup (NYSE: C) has a cautious but gradually improving dividend policy. After a drastic cut during the 2008 financial crisis (when the quarterly dividend was slashed to just $0.01), Citi resumed growing payouts in the 2010s. In recent years, the bank’s common dividend has inched upward – from an annual $1.92 per share in 2019 to $2.08 in 2023 (^[1]). The current quarterly dividend stands at $0.53 per share, and Citi’s board has signaled an intent to maintain at least this level, market conditions permitting (^[1]). At the current stock price, this equates to a dividend yield in the mid single-digits (approximately 3–4%), providing investors with a meaningful income stream. Citi also supplements dividends with buybacks; in 2023, it returned $6.1 billion to common shareholders – about $4.1 billion in dividends and $2.0 billion in share repurchases (^[1]). This represented a 76% total payout of annual earnings (^[2]), reflecting an effort to balance capital return with regulatory capital needs. Notably, the dividend payout ratio (dividends as a percentage of net income) was around 51% for 2023, up from just 20–30% in prior years (^[1]) due to a dip in earnings. Overall, Citi’s dividend appears well-covered by earnings and remains subject to Federal Reserve oversight – annual stress tests effectively cap how much Citi can pay out through dividends and buybacks. Management’s commitment to at least the current dividend level (^[1]), even as it navigates a major transformation, signals confidence in the bank’s underlying earnings stability. Investors can likely expect modest dividend growth going forward, albeit at a measured pace given regulatory constraints.

Leverage and Debt Maturities

Citigroup’s balance sheet is large and levered, as is typical for a global bank. Customer deposits are the primary funding source – Citi had about $1.31 trillion in deposits as of year-end 2023 (^[1]). These deposits (checking, savings, time deposits, etc.) form a relatively stable, low-cost funding base, but they can re-price or flee if clients lose confidence. Supplementing deposits, Citi also relies on wholesale funding: it had $286.6 billion in long-term debt outstanding (^[1]). This debt is a mix of senior and subordinated bonds, some issued by the parent holding company and others by banking subsidiaries. Citi staggers its debt maturities to manage refinancing risk. As of the end of 2023, roughly $45.8 billion of Citi’s long-term debt is scheduled to mature in 2024, with a similar $46.4 billion due in 2025 (^[1]). Maturities taper off to about $40.4 billion in 2026 and smaller amounts in 2027–2028, with about $102.6 billion of debt coming due from 2029 onward (^[1]). This laddered schedule helps Citi avoid a heavy concentration of debt coming due at any one time. The bank has been proactive in managing its liabilities – in 2023, it even repurchased or redeemed approximately $32 billion of outstanding debt to reduce funding costs and take advantage of favorable market conditions (^[1]). Overall leverage (measured as assets-to-equity or a regulatory leverage ratio) is high in absolute terms, but that is normal for banks. Citi’s asset-to-equity is roughly 10:1 (Citigroup had ~$2.4 trillion of assets vs. ~$188 billion of common equity in 2023 (^[1])), in line with peers. Importantly, Citi’s regulatory capital ratios indicate a strong capital buffer – providing a cushion for this leverage, as discussed next.

Earnings Coverage & Capital Adequacy

In evaluating Citi’s dividend sustainability and debt coverage, the bank’s earnings and capital profile are crucial. Citi generated $9.2 billion in net income in 2023 (^[2]), and its dividend payout (common dividends of ~$4.1 billion (^[1])) was well covered by those earnings. The dividend coverage ratio – effectively the inverse of payout ratio – was comfortable, meaning Citi is paying out roughly half its profits and retaining the rest to build capital. Beyond the income statement, Citi’s regulatory capital metrics underscore its ability to absorb losses and meet obligations. As of Q4 2023, Citigroup’s Common Equity Tier 1 (CET1) capital ratio stood at 13.3% (^[2]), well above regulatory minimum requirements (which for Citi are around ~10% when including buffers for stress tests and global systemically important bank surcharges). A 13.3% CET1 ratio implies that Citi’s core equity capital equates to 13.3% of its risk-weighted assets – a healthy margin that can protect creditors and depositors in a downturn. Citi’s Tier 1 leverage ratio (Tier 1 capital to total exposures) is also solid, and the bank meets Total Loss-Absorbing Capacity (TLAC) requirements with a substantial chunk of long-term debt qualifying as bail-in capital. In practical terms, Citi’s recurring earnings (from interest and fees) comfortably cover its interest costs on debt – traditional “interest coverage” ratios are less meaningful for banks, since interest expense is part of operating costs managed via net interest margin. Citi’s net interest income was $45 billion in 2023 (^[1]), easily exceeding its interest expense, which illustrates that the bank is generating ample income to pay deposit interest and bond coupons. Overall, coverage of obligations is strong: dividends consume a moderate share of profits, and capital levels provide a buffer to continue debt service even under stress. However, Citi’s management remains prudent – for example, they’ve indicated that any share buybacks will be assessed quarter-by-quarter given the uncertain regulatory capital outlook (^[1]). This cautious stance on capital return ensures that Citi’s leverage stays safe and that both bondholders and dividend investors have a margin of safety.

Valuation and Peer Comparisons

Despite recent improvements, Citigroup’s stock continues to trade at a discounted valuation relative to major banking peers. One key metric for bank stocks is price-to-book ratio (P/B) – and Citi’s P/B is markedly low. As of early 2025, Citi was valued at roughly 0.69× book value, meaning the stock price was only about 69% of the company’s accounting book value per share (^[3]). By contrast, rivals like JPMorgan Chase traded around 2.1× book and Bank of America around 1.25× book (^[3]), reflecting investors’ higher confidence in those banks’ profitability and stability. Even after a strong rally in 2025 (Citi’s share price climbed about 36.5% year-to-date through October (^[4])), the stock still has the lowest P/B among large U.S. banks (^[4]). This deep discount suggests that the market remains cautious on Citi – essentially pricing it for lower returns on equity and higher risks than peers. In terms of earnings multiples, Citi also trades cheaply. The stock changes hands at roughly 8–10× forward earnings, a single-digit P/E ratio that is below the market average and below more premium-valued banks. Citi’s tangible book value per share is about $85–$90 (lower than GAAP book due to goodwill and deferred tax assets), and notably the stock has only recently approached that tangible book level (^[5]) after a long period of trading at a discount. Investors’ skepticism ties to Citi’s historically subpar profitability – its return on tangible common equity (ROTCE) has lagged peers, in the mid-single digits until recently. However, under CEO Jane Fraser’s ongoing turnaround, Citi’s ROTCE has improved to around 8–9% in 2025, and management is targeting ~10–11% by 2026 (^[5]) (^[6]). If Citi can deliver that targeted uptick in ROE, the current valuation gap could begin to close. For now, though, valuation remains a point of both opportunity and caution: opportunity, because some analysts see the stock as undervalued (Wells Fargo recently called Citi a “dominant pick” with potential to double over three years, citing its discounted metrics (^[3])); and caution, because the low multiples also reflect persistent concerns (discussed below) that Citi must overcome to earn a higher market rating.

Key Risks

Every bank faces external and internal risks, and Citigroup is no exception. Some of the key risk factors for Citi include:

– Economic & Credit Cycle Risk: Citi’s fortunes are tied to the global economy. In a recession or credit crisis, loan defaults would rise and deal-making would dry up, hurting Citi’s earnings. The Federal Reserve’s stress tests indicate Citi could be more impacted by a severe downturn than peers – in recent Fed scenarios, Citi’s capital ratios dropped more sharply than those of JPMorgan or Bank of America (^[5]). This suggests Citi’s mix of assets (and perhaps lower pre-provision earnings) makes it somewhat more vulnerable in a bad-case scenario (^[5]). A deteriorating macro environment (e.g. surging unemployment or a financial shock) is a perennial risk for big banks like Citi, which would face higher credit losses across consumer and corporate lending portfolios.

SPECIAL ALERT

Worried About a $36T Debt Bomb? Secure Your Retirement With Gold

Quick read • Proven strategy • Trusted experts

FREE PDF

Tap to protect →

– Regulatory & Capital Requirements: Banks operate under strict regulatory oversight. Citi’s capital and liquidity rules could tighten further – for instance, U.S. regulators have proposed updates to Basel III capital standards that would significantly raise risk-weighted assets for large banks. Citi has warned that if these proposals are finalized as initially outlined, they would have a “material adverse impact” on the bank (^[1]), effectively forcing Citi to hold more equity capital against its assets. That could constrain returns and dividends. Additionally, Citi is subject to the Federal Reserve’s Stress Capital Buffer (SCB) regime; if Citi’s risk profile or stress test results worsen, its required capital buffers (and thus limits on payouts) could increase. Ongoing regulatory scrutiny (e.g. CCAR stress tests, resolution planning, and international rules) remains a risk, as does the potential for new rules on everything from capital to consumer protections that could raise costs or limit certain activities.

– Interest Rate & Market Risk: As a bank, Citi faces interest-rate risk – the risk that changes in rates compress its margins or reduce borrowing demand. The rapid rate hikes over the past year boosted Citi’s net interest income initially (as loan yields jumped), but also increased competition for deposits (raising Citi’s interest expense). If yield curves invert or economic conditions shift, net interest margin could come under pressure. Furthermore, Citi’s trading and investment banking revenues are exposed to market conditions; volatility can help trading profits, but extreme market stress could lead to losses. A mismanagement of interest-rate risk (e.g. mismatches in asset-liability durations) can be costly – although Citi, as a globally systemic bank, has extensive risk management processes to mitigate this. Still, the memory of past missteps (like Citi’s huge trading losses in the 2008 crisis) means investors remain watchful of market risk appetite.

The One Material Everyone Will Be Begging For

Spruce Pine's 99.9999999% pure quartz powers the chips and the future. Adam O'Dell shows which infrastructure names will sell the picks & shovels.

Claim Your Free Pack

– Global Operational Risk: Citi operates in over 90 countries, which introduces operational complexities and risk. Currency fluctuations, geopolitical events, or political instability in certain regions (Asia, Latin America, etc.) can impact the bank. Moreover, running a sprawling institution means Citi is exposed to technology and cybersecurity risks, compliance failures, and human errors. Unfortunately, Citi has had notable operational lapses in recent years – for example, an infamous incident where Citi mistakenly made an $900 million payment to third parties, and more recently an operational error that led to an $81 trillion erroneous credit entry (quickly corrected) (^[5]). These kinds of issues underscore operational and control risks. Such errors can result in financial losses or regulatory penalties – indeed, in 2024 Citi paid a $136 million fine to U.S. regulators over long-standing internal control deficiencies (^[5]). Continued focus on improving internal systems and oversight is critical to reducing this risk.

– Competition & Strategic Execution: Citi faces intense competition from other banks and fintechs across its businesses – from JPMorgan in global banking, to fintech startups in consumer payments, to regional banks in U.S. lending. If Citi cannot keep up in technology or fails to offer compelling services, it risks losing market share or seeing its margins erode. Additionally, a core strategic risk is whether Citi can successfully execute its ongoing transformation plan. CEO Jane Fraser has embarked on a major reorganization (exiting consumer banking in many foreign markets, selling non-core assets, and focusing on wealth management and institutional clients). Execution missteps – such as delays in divestitures or failure to control expenses – could undermine the expected benefits. For instance, Citi has targeted significant cost cuts, but so far expense reductions have only barely met goals (^[5]), and the bank’s efficiency ratio still lags peers. If promised efficiencies don’t materialize, Citi’s profitability might remain subpar. Likewise, any failure to resolve the remaining Banamex (Mexico) consumer unit exit smoothly could create ongoing earnings drag or additional charges. In short, Citi must navigate a competitive landscape while delivering on its strategic overhaul – any stumble in this effort is a risk that could disappoint investors.

Red Flags and Recent Concerns

While Citi is making progress, investors and regulators have noted a few red flags in the past couple of years that are worth highlighting:

Free Briefing: What to do if the dollar drops 15–20%

★★★★★

“Helped me re-balance my retirement into hard assets before the market reacted — fast, professional, and clear.” — Satisfied Client

Protect My Retirement — Send the Briefing

– Operational & Control Lapses: As noted, Citi’s internal controls have come under scrutiny. The bank has a history of operational errors – a headline example being the mistaken multi-billion dollar payment in 2020, and more recently an $81 trillion erroneous internal transaction entry (^[5]) (an eye-popping number, though it was quickly rectified). Such incidents suggest that Citi’s systems and processes were, or in some areas still are, in need of improvement. Regulators took notice: in 2020 the OCC and Fed fined Citi $400 million for risk management deficiencies, and in 2024 the Federal Reserve hit Citi with another $136 million fine for not correcting those issues fast enough (^[5]). These red flags around control weaknesses indicate execution risk in Citi’s transformation – management must ensure the “plumbing” of the bank is fixed to prevent costly mistakes. The good news is Citi has invested heavily in technology and risk management upgrades as part of its consent orders, but until a clean bill of health is given, this remains a concern.

– Regulatory Compliance Issues: Beyond fines for operational controls, Citi has faced other regulatory and legal challenges. For instance, Citi has had to improve its anti-money-laundering (AML) and Know-Your-Customer processes after past citations. Any major compliance failure could result in further penalties or restrictions. The Federal Reserve’s annual stress test results have also flagged Citi as relatively more stressed under adverse scenarios, which, while not a compliance issue per se, raises a red flag about capital resilience (as discussed, Citi’s capital drops more than peers in the Fed’s hypothetical severe recession scenario (^[5])). Additionally, Citi’s plan to eventually separate its Mexican retail bank (Banamex) is under the eye of regulators in both the U.S. and Mexico – any hiccup in that process could invite regulatory intervention. Overall, while Citi is financially sound, its regulatory report card has had blemishes that the bank is still working to clear.

– Earnings Quality & Return Gap: Another flag for investors is Citi’s ongoing profitability gap versus peers. Citigroup’s return on equity has persistently lagged, due in part to past crisis-era losses that left it with a large deferred tax asset (DTA) and a restructured business mix. Even now, with ROTCE improving to ~9%, it is still below management’s target and well below JPMorgan’s ~20%+ ROTCE. This raises a concern that Citi’s franchises (global trading, treasury & transaction services, U.S. credit cards, etc.) are solid but not stellar enough to achieve peer-level returns. The bank effectively acknowledged this by lowering its medium-term ROTCE goal to ~10–11% (from a higher earlier target) (^[6]). While not a “red flag” in the sense of a scandal, the lowered ambition is a sober admission that hitting even low double-digit returns will take time. Investors might view this as a cautionary signal – Citi’s turnaround, while real, is only half-done (^[5]). The stock’s cheap valuation reflects this skepticism. If future earnings continue to underwhelm or targets get pushed out further, it could reinforce the market’s cautious stance on Citi.

– Lingering Franchise Issues: Finally, some analysts point to the fact that Citi’s business model is still complex and reliant on certain volatile segments. For example, Citi has a sizable international footprint and capital markets operation, but lacks the domestic retail banking dominance of a Chase or the asset management heft of some peers. Citi’s attempt to sell or IPO Banamex is itself due to an underperforming asset – it remains to be seen if Citi can cleanly separate that unit without incurring major losses or if it will need to retain some exposure. Any signs of buyer difficulty or delays in the Banamex exit might be read as a red flag that the reshaping of Citi is not going as smoothly as planned. Similarly, if Citi’s vaunted Services division (Treasury and Trade Solutions) or its Wealth Management push do not deliver growth as expected, it could indicate that Citi’s path to a higher ROE is bumpier than hoped. In summary, most of Citi’s red flags revolve around execution and performance – the bank must prove that it can operate without costly errors and that it can boost its profitability; until then, some caution lights will continue flashing.

Open Questions & Outlook

Looking ahead, there are several open questions about Citigroup’s trajectory that investors will be watching:

– Can Citi Hit Its Profitability Targets? The central question is whether Citi will achieve the improved returns it has promised. Management aims for a 10–11% ROTCE by 2026 (^[5]), up from ~8–9% recently. This hinges on executing cost cuts, growing revenue in focus areas (like wealth management), and freeing up capital from asset sales. If Citi meets or beats this target, it could go a long way toward closing the valuation gap. But if these efficiency and revenue goals slip, Citi might remain stuck with middling returns. Achieving double-digit ROTCE will likely determine if Citi’s stock re-rates upward or languishes at a discount.

– How Will the Banamex Exit Play Out? Citi’s planned exit from its Mexico consumer banking unit (Banamex) is a major strategic move in progress. Initially, Citi sought to sell the entire Banamex franchise, but talks with potential buyers fell through. In 2025, Citi instead sold a 25% stake in Banamex to a Mexican investor for $2.3 billion (^[7]) (^[4]), and reportedly rejected a larger $9+ billion bid for the whole unit as too low (^[8]). Now, Citi is exploring an IPO of Banamex or bringing in additional minority investors (^[9]). The open question is: what is Citi’s next move for Banamex and will it unlock value? If Citi can fully divest Banamex via a public listing or piecemeal sales at a decent valuation, it would release capital and management focus. However, if the process drags on or the market assigns a low value to Banamex, Citi might not realize much upside. The outcome will influence Citi’s capital return plans and strategic focus on its core businesses.

– Will Regulatory Changes Derail Capital Returns? Regulators are in the midst of recalibrating big bank capital rules. The prospect of higher capital requirements (from the Basel “endgame” proposals and a stricter stress test regime) raises uncertainty. Citi has already tempered its shareholder return ambitions by trimming its ROTCE outlook (citing “investment needs” which include building capital) (^[6]). The question is how much more capital might Citi need to retain if these rules tighten, and what that means for dividends and buybacks. Investors will be watching the Federal Reserve’s annual stress test results and final Basel III implementation details. If Citi comfortably clears its regulatory hurdles, it can continue robust buybacks (notably, it announced a $20 billion share repurchase program for 2025 (^[6])). If not, capital return could be curtailed. Thus, a key open question is whether regulatory capital demands will cap Citi’s upside or if the bank can optimize its balance sheet to meet new rules without sacrificing returns.

– Can Citi Operate Without Further Missteps? As discussed in “red flags,” Citi’s operational overhaul is ongoing. A forward-looking question is: Has Citi truly fixed its internal issues? The coming years will test whether the bank’s investments in risk controls, compliance, and technology have paid off. Ideally, we should see an absence of major snafus (no large erroneous payments, no new regulatory penalties) and improvement in regulatory feedback. Citi getting out from under consent orders and notching a “satisfactory” rating in regulatory exams would affirm that the ship has been righted. This remains to be seen. Any unexpected blunder would not only be costly but also damage management’s credibility in executing a safe transformation. So far, CEO Jane Fraser has earned cautious praise for steering the bank forward (^[3]), but continued vigilance is required. Stakeholders are essentially asking: can Citi shed its historical reputation for complexity and mistakes, and emerge as a simpler, well-controlled bank? The answer will unfold over the next couple of years.

– Will the Valuation Gap Close – and How? Finally, an overarching question is whether and how Citi’s persistent valuation discount might narrow. If Citi delivers on performance (higher ROTCE, stable growth), one would expect its P/B and P/E multiples to rise closer to peer levels. In fact, Wells Fargo’s bank analysts argued Citi’s stock could double in three years with successful execution (^[3]), which implies a re-rating from the current depressed multiples. However, skepticism remains: Citi has teased turnarounds before that didn’t fully materialize. It is possible the stock will need an external catalyst – for example, an economic tailwind or an outright breakup/major asset sale – to realize value. Some have even speculated whether Citi would consider more radical moves (like spinning off its Institutional Clients Group or merging with another bank) if the stock stays too cheap. While no such plans are evident, investors are keen to see some catalyst that unlocks shareholder value. In summary, the open question is whether Citi’s steady, internally driven transformation will be enough to change market perceptions, or if extraordinary measures (and patience) are needed. The trajectory of Citi’s share price and valuation metrics over 2025–2026 will likely answer that question.

NewAmsterdam’s Inducement Grants – A Side Note

Apart from Citigroup’s banking narrative, an interesting development has emerged in the biotech sector that tangentially involves Citi’s sphere of influence. NewAmsterdam Pharma (NASDAQ: NAMS) – a late-stage biopharmaceutical company – recently reported the issuance of inducement equity grants as it beefs up its leadership team. On January 9, 2025, NewAmsterdam’s board approved inducement stock option grants covering 58,000 shares for two new hires and 170,800 shares for Maryellen McQuade, the company’s incoming Chief People Officer (^[10]). These stock options were granted with an exercise price of $25.94 (equal to the stock’s market price at grant) and will vest over four years (^[10]). In addition, NewAmsterdam granted 36,600 restricted stock units (RSUs) to the new Chief People Officer, vesting over three years (^[10]). The grants were made under a special 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) (^[10]) – which allows companies to issue equity awards to new employees outside of shareholder-approved plans, as a material inducement to employment. In plain terms, these inducement grants are a way for NewAmsterdam to attract top talent by offering a stake in the company’s future growth.

For Citigroup, NewAmsterdam’s moves are notable because they highlight the kind of high-growth, high-risk companies that Citi’s capital markets and research arms engage with. Citigroup was one of the banks that took NewAmsterdam public via a SPAC merger in 2022, and Citi’s analysts now actively cover the stock. In mid-2025, Citigroup’s equity research team initiated coverage on NewAmsterdam Pharma with a bullish “Buy” rating and a $42 price target (^[11]), reflecting confidence in the biotech’s prospects. The inducement grants underscore NewAmsterdam’s efforts to recruit talent and advance its drug pipeline (focused on cardiovascular disease treatments). For investors reading Citi’s research or considering biotech allocations, such developments are a reminder that small-cap biotech firms often rely on equity compensation to lure experienced executives – which can be dilutive, but is standard practice in the industry. While NewAmsterdam’s inducement grants don’t directly impact Citigroup, they illustrate the broader ecosystem Citi operates in: the bank not only manages its own capital and strategy, but also facilitates growth for emerging companies. Citi’s involvement – whether as an underwriter, advisor, or analyst – in stories like NewAmsterdam’s suggests that Citigroup’s next moves aren’t confined to traditional banking. They extend into nurturing new corporate clients in innovative fields, potentially benefiting Citi through fees and market intelligence. Investors in Citi might take comfort that the bank has its finger on the pulse of such trends, even as they remain focused on Citi’s core metrics like dividends, leverage, and returns. NewAmsterdam’s case is a small but telling example of how Citi’s wide reach in the financial world can intersect with headline-grabbing news in other sectors – and it emphasizes the importance of having knowledgeable talent on both the banking and corporate side, sometimes aided by inducement incentives to bring that talent on board (^[10]) (^[10]).

Sources: Citigroup 2023 Annual Report (Form 10-K) (^[1]) (^[1]) (^[1]); Citi Q4 2023 Earnings Press Release (^[2]) (^[2]); Reuters news on Citi’s performance and strategy (^[4]) (^[3]) (^[5]); Citigroup investor presentations and SEC filings on capital and debt (^[1]) (^[1]); Reuters Breakingviews analysis on Citi’s turnaround progress (^[5]) (^[5]); Reuters news on Banamex sale attempts (^[7]) (^[8]); NewAmsterdam Pharma press release (Globe Newswire) on inducement grants (^[10]) (^[10]); Market data and Citi research notes on NewAmsterdam (^[11]). All information is up to date as of December 2025.

Sources

For informational purposes only; not investment advice.